Safety and Efficacy of Bone Marrow Derived MNCs for Treatment of Cells for the Treatment of Hunting Tons Chorea.

Safety and Efficacy of Bone Marrow Derived MNCs for the Treatment of Huntingtons Chorea. It is Self Funded (Patients' Own Funding) Clinical Trial

Status

UNKNOWN

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01834053

Acronym

BMACHC

Enrollment

Registered

2013-04-17

Start date

2014-09-30

Completion date

2016-06-30

Last updated

2014-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Huntington Disease

Keywords

Huntington Disease,stem cell therapy

Brief summary

This study is Single arm, Single Centre trial to check the Safety and Efficacy of Bone Marrow Derived Autologous mononuclear cell {MNC} (100 Million per dose).trial to be conducted for 36 months in patients with diabetes Mellitus in India,Primary outcome measure are Improvement in cognitive and Psychiatric Symptoms and Improvement in Jerky,random, and Uncontrollable Movements called Chorea.

Detailed description

This study is Single arm, Single Centre trial study the Safety and Efficacy of Bone Marrow Derived Autologous mononuclear cells (MNCs) ,to be conducted for 36 months in patients with diabetes Mellitus in India,Primary outcome measure are Improvement in cognitive and Psychiatric Symptoms and Improvement in Jerky,random, and Uncontrollable Movements called Chorea.

Interventions

BIOLOGICALautologous Stem Cell

Intrathecal transplantation of autologous 100 millions Stem cells{MNCs } per dose'

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

35 Years to 44 Years

Healthy volunteers

Yes

Inclusion criteria

* Patient should suffer from Hunting tons Chorea, * Hunting tons chorea commonly become noticeable between the ages of 35 -44 * Willingness to undergo Bone Marrow derived Autologous cell Therapy. * Ability to comprehend the explained protocol and thereafter give an informed consent as well as sign the required Informed Consent form(ICF) for the study. * Ability and willingness to regular visit to hospital for protocol procedures and follow up

Exclusion criteria

* Patient with History of Immunodeficiency HIV+,Hepatitis B virus ( HBV) and History of Life threatening allergic or immune -Mediated Reaction. the site of bone marrow aspiration potentially limiting Procedure. * alcohol and drug abuse / dependence. * Severe skin infection. * Haemodynamically unstable. =subject with primary and secondary diabetes , Insulin dependence. * Neurological disease caused by autoimmune or genetic cause. * patients suffering from peripheral muscular dystrophy.

Design outcomes

Primary

Measure	Time frame
Improvement in Cognitive and psychiatric symptoms	6 Months

Secondary

Measure	Time frame	Description
Improvement in neuropsychiatric behaviour	6 Months	—
Increase in life expectancy	6 Months	Increase in life expectancy.Time period- 6 Months
Improvement in writhing motions or abnormal posturing	6 month	-Improvement in writhing motions or abnormal posturing
Improvement in compulsive behaviour	6 month	—

Countries

India

Contacts

Primary ContactSachin P Jamadar, D Ortho

sac2751982@gmail.com+918888788880

Backup ContactSmita S Bhoyar, B.A.M.S.PGCR

drsmitabhoyar@rediff.com9372620569

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026